Sie sind auf Seite 1von 1

bs_bs_banner

Heads Up

Reference Scabies control with ivermectin


1 Patrick SW et al. Pediatrics 2016; 137: e20152901.
Reviewer: David Isaacs, Children’s Hospital at Westmead, Sydney Infestation with the mite Sarcoptes scabiei causes an extremely itchy
(david.isaacs@health.nsw.gov.au) rash, scabies, which can be complicated by impetigo due to Staphy-
lococcus aureus or Streptococcus pyogenes. In tropical environments in-
cluding Northern Australia and the Pacific, impetigo can cause
pyogenic complications, but serious non-pyogenic complications
Kangaroo Mother Care and neonatal
of S. pyogenes infection include rheumatic fever and glomerulone-
outcomes: A meta-analysis
phritis. Consequently, scabies control might reduce rheumatic
heart disease. An innovative study randomised three island com-
Kangaroo Mother Care (KMC) originated in South America munities in Fiji to one of three interventions for scabies: standard
as a low cost alternative to incubators for low birth weight care (topical permethrin to affected persons and contacts,
(LBW) infants. The key feature of KMC is early, continu- n = 803); permethrin (mass administration of permethrin,
ous, and prolonged skin-to-skin contact between LBW n = 532); or ivermectin (mass administration of single-dose oral
newborn and mother. Ideally, KMC also includes exclusive ivermectin, n = 716).1 Ivermectin was taken under direct observa-
breastfeeding; early hospital discharge; and close follow-up at tion. Before treatment, the prevalence and severity of scabies was
home. A recent systematic review and meta-analysis exam- similar. The prevalence of scabies declined in all three groups over
ined the association between KMC and neonatal outcomes.1 the 12-month intervention period: standard care group by 49%
A total of 124 studies met inclusion criteria, of which half (95% confidence interval (CI) 37–60%), permethrin group by
were randomized controlled trials and the others observa- 62% (95% CI 49–75%) and ivermectin group by 94% (95% CI
tional. Results were resoundingly positive. Among LBW new- 83–100%). The prevalence of impetigo also decreased significantly
borns, KMC (compared to conventional care) was associated in all groups: relative reduction 32% (95% CI 14–50%), 54%
with a 36% reduction in mortality (RR = 0.64; 95% CI 0.46 (95% CI 35–73%) and 67% (95% CI 52–83%), respectively. The
to 0.89). KMC also significantly decreased risk of neonatal decrease in impetigo in the ivermectin group was significantly
sepsis (RR = 0.53; 95% CI 0.34 to 0.83); hypothermia greater than in the other two groups (P < 0.05). Adverse events,
(RR = 0.22; 95% CI 0.12 to 0.41); hypoglycemia (RR = 0.12; mostly itch and headache, were more common in the ivermectin
95% CI 0.05 to 0.32); hospital re-admission (RR = 0.42; than the permethrin group (15.6% vs. 6.8%) but were mild. Mass
95% CI 0.23 to 0.76); and increased exclusive breastfeeding administration of ivermectin is safe and reduces both scabies and
(RR =1.50; 95% CI 1.26 to1.78). Not surprisingly, the au- impetigo.
thors concluded; “interventions to scale up KMC implementa-
tion are warranted”.

Reference Reference
1 Boundy EO et al. Pediatrics 2016; 137: 1–16. 1 Romani L et al. N. Engl. J. Med. 2015; 373: 2305–13.

Reviewer: Craig Mellis, Sydney Medical School, University of Sydney, Reviewers: David Isaacs, Philip Britton, Children’s Hospital at
Sydney (craig.mellis@sydney.edu.au) Westmead, Sydney (david.isaacs@health.nsw.gov.au)

Journal of Paediatrics and Child Health 52 (2016) 578–579 579


© 2016 Paediatrics and Child Health Division (The Royal Australasian College of Physicians)

Das könnte Ihnen auch gefallen